**Results**

**Antibody-dependent cellular cytotoxicity (ADCC) by NK cells**

Purified human NK cells were cultured overnight with or without NKTR-255. Activated NK cells (effector cells) were co-cultured with cetuximab pre-coated FaDu (HNSCC) or HCT-116 (colorectal cancer) cells (target cells). The co-culture was evaluated by detecting 7-AAD stained target cells (*, p<0.05 relative to no treatment, #, p<0.05 relative to cetuximab + CD16 Fc receptor crosslinking).

**NKTR-255 enhances cetuximab mediated NK cells ADCC against HNSCC and colorectal cancer cell lines in vitro.**

**Conclusions**

**NKTR-255 enhances tumor growth inhibition activity in human tumor xenograft models in mice**

**References**


2. Wei et al. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. AACR. 2019, Poster 3265.